Search Results - "Lydon, C.A."

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer by Hastings, K., Yu, H.A., Wei, W., Sanchez-Vega, F., DeVeaux, M., Choi, J., Rizvi, H., Lisberg, A., Truini, A., Lydon, C.A., Liu, Z., Henick, B.S., Wurtz, A., Cai, G., Plodkowski, A.J., Long, N.M., Halpenny, D.F., Killam, J., Oliva, I., Schultz, N., Riely, G.J., Arcila, M.E., Ladanyi, M., Zelterman, D., Herbst, R.S., Goldberg, S.B., Awad, M.M., Garon, E.B., Gettinger, S., Hellmann, M.D., Politi, K.

“…Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however,…”
Get full text

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma by Boiarsky, D., Lydon, C.A., Chambers, E.S., Sholl, L.M., Nishino, M., Skoulidis, F., Heymach, J.V., Luo, J., Awad, M.M., Janne, P.A., Van Allen, E.M., Barbie, D.A., Vokes, N.I.

“…Prior studies characterized the association of molecular alterations with treatment-specific outcomes in KRAS-mutant (KRASMUT) lung adenocarcinoma (LUAD). Less…”
Get full text